CD79A and myeloid sarcoma: This study provides Class IV evidence that, in MS patients without recent inflammatory activity, treatment with ocrelizumab is associated with elevated BAFF levels, which correlate with reductions in IgG and IgA, and with increased serum markers of neuroaxonal damage and inflammation.